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OBJECTIVES: As Type 2 Diabetes (T2D) progresses oral hypoglycaemic agents
(OHAs) alone fail tomaintain blood glucose control and insulin is required. LAPTOP
was a multi-national study comparing the addition of once daily insulin glargine
(IG, Lantus Solostar) to glimepiride and metformin with twice daily 30% regular/
70% human NPH insulin (Actraphane 30) without any additional OHAs in 371 T2D
patients over a 24 week period. IG plus OHAs was significantly more effective in
lowering HbA1C (1.64% vs1.31%). A cost minimisation analysis was undertaken
using LAPTOP data to compare the costs of the 2 regimens.METHODS:The analysis
was undertaken from a UK NHS perspective with prices from MIMS November
2010. Cost estimates were based on the use of non-proprietary OHAs and IG and
biphasic insulin aspart (BIA, NovoMix 30 FlexPen) prefilled disposable injection
devices. It was assumed anewneedle, lancet and blood glucose test stripwere used
for each injectionwith a 2Upriming dose of insulin before each injection.RESULTS:
Costs were calculated over the 24 week study period. The total cost of drugs per
patient on IG plus OHAs was slightly lower than BIA at £130 and £167 respectively
despite no OHA use in the BIA group (final mean insulin doses at 24 weeks IG 28.2U
and BIA 64.5U). The cost of needles, lancets and test strips was much lower for IG
plus OHAs at £76 comparedwith £152 for the BIA group. Overall the cost per patient
for 24 weeks for the IG plus OHAs group was £206 compared with £319 for BIA, a
difference of 35%. Sensitivity analyses replacing disposablewith reusable pens and
BIA by other biphasic insulins gave similar results to the base case. CONCLUSIONS:
In comparison with biphasic insulin the cost of IG plus OHAs was 35% less to
achieve an equivalent reduction in HbA1C.
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OBJECTIVES: To examine the impact of treatment modifications on healthcare
expenditure for patients with type 2 diabetes (T2D) initiating exenatide BID (ex-
enatide) or insulin glargine. METHODS: A retrospective database analysis com-
prised of adult patients with T2D who initiated exenatide (N9197) or insulin
glargine (N4499) between 10/01/2006 and 03/31/2008 with 12 months pre- and 18
months post-index continuous enrollment. The 2 cohorts were 1:1 propensity
score matched on baseline demographics, clinical, and resource utilization vari-
ables. Treatment modification was defined as the first event intensification,
switching, or discontinuation of the index medication. The mean healthcare ex-
penditures in all patients and those experiencing treatment modifications were
estimated usingmultivariate regression. RESULTS: Baseline characteristics of pa-
tients on exenatide (n3774) and glargine (n3774) were well balanced after
matching with mean age of 57 years, mean Deyo Charlson Comorbidity score of
1.6, and proportionately more males (54%) in both cohorts. Glargine-treated
patients were 33%more likely to modify their treatment than exenatide-treated
patients (Hazard Ratio [HR]: 1.33, p0.0001). Compared to exenatide-treated
patients, glargine-treated patients were more likely to intensify (HR1.72,
p0.0001), or discontinue their treatment (HR1.25, p0.0001), but less likely to
switch to new therapy (HR0.71, p0.0001). Mean healthcare expenditure was
significantly lower for exenatide compared to glargine after 18 months (differ-
ence  $1667, p0.0001). Exenatide-treated patients who continued their treat-
ment had significantly lower expenditure of $1546 (p0.005) and those who
intensified their therapy also had significantly lower expenditure of $2472
(p0.001). There were no significant differences in expenditure for patients who
switched or discontinued their therapy. CONCLUSIONS: The likelihood of treat-
ment modification and mean total healthcare expenditure varied for patients ini-
tiating exenatide or glargine in real-world settings. Exenatide-treated patients had
lower mean healthcare expenditure compared to glargine-treated patients. Ex-
enatide-treated patients who continued or intensified their therapy also had asso-
ciated reduction in medical expenditure.
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OBJECTIVES: We compared healthcare resource utilization (HRU) and costs asso-
ciated with add-on therapy of RSG versus STG to MET.METHODS: Type II diabetes
mellitus patients, 18 years, initiating RSG or STG (first dispensing  index date)
add-on therapy with MET were identified in the PharMetrics database (1999-2008).
Patients were continuously enrolled for 6 months pre-index (baseline) and 12
months post-index, had 1 dispensing for MET in the 6-month pre-index period,
did not use insulin or sulfonylurea, and were treated with RSGMET before 05/01/
2007 or STGMET for 6 months post-index. All-cause and diabetes-related HRU
and annual costs ($2008) were reported for the 12-month follow-up period. Work-
loss costs were estimated by applying hourly wage from the Bureau of Labor Sta-
tistics tomissedwork hours (hospitalization8 hours; outpatient/emergency room
[ER] visit4 hours). Multivariate analyses were conducted, adjusting for baseline
demographics, comorbidities, and costs. RESULTS: Compared to STGMET cohort
(N1,660) at baseline, RSGMET cohort (N3,731) was younger (55 vs. 58 years)
with fewer comorbidities (Charlson Comorbidity Index [0.26 vs. 0.34]), and had
lower total costs (RSGMET: $7,875; STGMET: $9,412; cost difference$1,536,
p0.0043). Frequency and costs of hospitalizations and ER visits were not different
at baseline. In the 12 months post-index period, all-cause HRU and corresponding
annual cost difference between RSGMET and STGMET cohorts was enlarged
(RSGMET: $8,443; STGMET: $10,757; cost difference$2,314, p0.0001). After ad-
justing for covariates, the cost decrease associated with RSGMET remained sta-
tistically significant (cost difference$1,248; cost ratio0.87; P0.0120). Diabetes-
related adjusted incremental cost saving of RSGMET over STGMET was $599
(cost ratio0.83, P0.0160). The adjusted workloss cost was also lower for
RSGMET compared to STGMET (cost difference$22, cost ratio0.93; P0.0120).
CONCLUSIONS: Compared to the newDPP-4 agent STG combinedwithMET, RSG, a
thiazolidinedione, combined with MET was associated with lower all-cause and
diabetes-related direct healthcare costs and indirect workloss costs.
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OBJECTIVES: To assess the cost of all-cause or cardiovascular disease-related
hospitalization in a real world setting among patients with type 2 diabetes
prescribed exenatide, a GLP-1 receptor agonist, compared to patients treated
with sulfonylureas or insulins. METHODS: Analyses included patients in the
LifeLink™ database initiating a new prescription for a glucose-lowering agent
between June 1, 2005 and March 31, 2009, without a prescription for the same
agent in the prior 9 months. Patients were followed for 12 months. Intention-
to-treat analyses of costs of all-cause and cardiovascular disease-related hos-
pitalization (myocardial infarction, stroke, or coronary revascularization), ad-
justed for differences in 300 clinical and demographic characteristics, were
compared using propensity-score-weighted methods. RESULTS: Mean age (SD)
was 53 (8) for patients treated with exenatide (n  14,400), 55 (12) for patients
treated with sulfonylureas (n  43,242), and 52 (12) for patients treated with
insulin (n  17,627); 43.4%, 53.5%, and 49.9% of patients treated with exenatide,
sulfonylureas, and insulin were male, respectively. More patients treated with
exenatide were obese (17.0%) than patients treated with sulfonylureas (7.4%) or
insulins (10.5%). Patients treated with exenatide were more likely to have hy-
perlipidemia (67.9%) than patients treated with sulfonylureas (49.9%) or insulins
(50.2%). Patients treated with exenatide had significantly lower mean (SD) all-
cause hospitalization costs than patients treated with sulfonylureas ($2,725 
16,463 Exenatide; $3,304  17,378 sulfonylureas; p 0.001) or insulin ($3,211 
17,969 Exenatide; $4,849  21,110 insulin; p 0.001). Patients treated with ex-
enatide also had significantly lower mean (SD) cardiovascular disease-related
hospitalization costs than patients treated with sulfonylureas ($428  6,174
Exenatide; $566  6,047 sulfonylureas; p 0.05) or insulin ($470  6,841 Ex-
enatide; $726  7,012, insulin; p 0.001). CONCLUSIONS: Exenatide treatment
was associated with significantly lower costs for all-cause and cardiovascular
disease-related hospitalization compared to treatment with sulfonylureas or
insulin.
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OBJECTIVES: To perform an economic evaluation of the use of gliperimide (GMP)
and the fixed-dose combination (FDC) of glimepiride/metformin (GMP/Met) in the
treatment of patients with DM-2, from the Mexican Public Health System
perspective.METHODS: TwoMarkovmodels were designed for reflecting different
treatment sequences.Model 1 is for not controlled diet and exercise andmetformin
intolerant patients, where GMP is compared to glibenclamide (GBC) and thiazoli-
dinedione (TZD). Model 2 is for patients which the lifestyle changed and themono-
therapy with metformin was insufficient for reaching a level of HbA1c7%, and a
sulfonylurea/Met FDC is compared to TZD/Met. The direct costs of the drug treat-
ment and the hypoglycemia episode were calculated. The dosage and efficacy of
the oral antidiabetic agents and insulin were established based on the literature
review and local practice. The unit costs were elicited from official sources. The
time horizon was three years, divided in quarterly cycles. RESULTS: Therapy with
GMP was dominant versus the treatment sequences which included a beginning
therapy with thiazolidinedione. The savings after three years with GMP or GMP/
Met instead of using TZD ranged from US$288.7 to US$632.1 per patient. Although
GBC has a low cost, it is associated with an increase in the mortality rate and
hypoglycemia events. A FDC of GMP/Met caused an incremental cost of 20% versus
GBC andmetformin separately. The average costs per additional life year obtain by
using GMP instead of GBC ranged from US$3,074.9 to US$3,261.4. The probabilistic
sensibility analysis shows that GMP and GMP/Met resulted as highly cost-effective
in approximately 90% of the simulations. CONCLUSIONS: Glimepiride mono-
therapy (model 1) and the administration of GMP/Met (model 2) represent highly
cost-effective health interventions regarding the use of glibencamide and it is dom-
inant versus the use of thiazolidinedione.
A95V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
